CCDC110: A Potential Drug Target for Cancer Treatment (G256309)

Target Name: CCDC110

NCBI ID: G256309

CCDC110

CCDC110: A Potential Drug Target for Cancer Treatment

CCDC110 is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and lymphoid organs. It is also a key component of the immune system, and has been shown to play a role in the development and progression of several types of cancer, including leukemia and melanoma.

Recent studies have identified CCDC110 as a potential drug target for the treatment of these cancers. By inhibiting the activity of CCDC110, researchers have found that they can inhibit the growth and spread of cancer cells, and potentially lead to a more effective treatment of these diseases.

One of the reasons why CCDC110 is considered a potential drug target is because it is involved in the development of cancer stem cells. Cancer stem cells are special cells that are able to give rise to all of the different types of cancer cells that can develop from a single cell. By targeting CCDC110, researchers have found that they can potentially disrupt the formation of cancer stem cells, which could lead to a more effective treatment of cancer.

Another reason why CCDC110 is considered a potential drug target is because it is involved in the development and progression of several types of cancer. For example, studies have shown that high levels of CCDC110 are associated with an increased risk of developing leukemia and melanoma. By targeting CCDC110, researchers have found that they can potentially reduce the risk of these cancers in people who are at high risk.

In addition to its potential role in the development and progression of cancer, CCDC110 is also considered a potential biomarker for several types of cancer. For example, studies have shown that CCDC110 levels are often elevated in the blood or lymph fluid of people with cancer. By measuring the levels of CCDC110 in these fluids, researchers have found that they can potentially diagnose cancer early on, when it is more easily treatable.

Overall, CCDC110 is a protein that has the potential to be a drug target for the treatment of cancer. By inhibiting its activity, researchers have found that they can potentially disrupt the formation of cancer stem cells and reduce the risk of several types of cancer. As more research is conducted on CCDC110, it is likely to become a valuable tool for the treatment of cancer.

Protein Name: Coiled-coil Domain Containing 110

The "CCDC110 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC110 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets